Depression decreases immunity and PD-L1 inhibitor efficacy via the hypothalamic–pituitary–adrenal (HPA) axis in triple-negative breast cancer

Sheng Yu(Anhui Medical University), Huaidong Cheng(Southern Medical University Shenzhen Hospital), Yinlian Cai(Anhui Medical University), Chen Gan(Anhui Medical University), Ling Jie Cheng(Anhui University of Traditional Chinese Medicine), Runze Huang(Anhui Medical University), Qianqian Zhang(Taishan Medical University), Wen Li(Anhui Medical University), Jianming Xu(Academy of Military Medical Sciences), Senbang Yao(Anhui Medical University)
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
November 22, 2024
10.1016/j.bbadis.2024.167581
Cited by 13

Related Papers

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
|The Lancet|2012|1.4k
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
|Journal of Clinical Oncology|2013|775
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
|The Lancet|2023|701
The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer
|Nature|2021|687
Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial
|The Lancet|2023|461